WO2019151767A1 - Composition containing lycopus lucidus turcz. extract as active ingredient for prevention, treatment, or alleviation of obesity - Google Patents
Composition containing lycopus lucidus turcz. extract as active ingredient for prevention, treatment, or alleviation of obesity Download PDFInfo
- Publication number
- WO2019151767A1 WO2019151767A1 PCT/KR2019/001281 KR2019001281W WO2019151767A1 WO 2019151767 A1 WO2019151767 A1 WO 2019151767A1 KR 2019001281 W KR2019001281 W KR 2019001281W WO 2019151767 A1 WO2019151767 A1 WO 2019151767A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- obesity
- extract
- composition
- prevention
- present
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 81
- 208000008589 Obesity Diseases 0.000 title claims abstract description 55
- 235000020824 obesity Nutrition 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 230000002265 prevention Effects 0.000 title claims abstract description 22
- 239000004480 active ingredient Substances 0.000 title claims abstract description 14
- 241000729196 Lycopus lucidus Species 0.000 title abstract description 5
- 239000008280 blood Substances 0.000 claims abstract description 32
- 210000004369 blood Anatomy 0.000 claims abstract description 32
- 230000037323 metabolic rate Effects 0.000 claims abstract description 13
- 230000037396 body weight Effects 0.000 claims abstract description 12
- 235000000346 sugar Nutrition 0.000 claims abstract description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 34
- 239000008103 glucose Substances 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 24
- 229910052746 lanthanum Inorganic materials 0.000 claims description 17
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 230000006872 improvement Effects 0.000 claims description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 229940123237 Taxane Drugs 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 12
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 10
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 8
- 235000013376 functional food Nutrition 0.000 claims description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 8
- 230000036541 health Effects 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 6
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 4
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 4
- 230000007407 health benefit Effects 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 235000009200 high fat diet Nutrition 0.000 abstract description 69
- 230000000694 effects Effects 0.000 abstract description 18
- 235000005911 diet Nutrition 0.000 abstract description 8
- 230000000378 dietary effect Effects 0.000 abstract description 6
- 238000010172 mouse model Methods 0.000 abstract description 6
- 208000002705 Glucose Intolerance Diseases 0.000 abstract description 4
- 201000009104 prediabetes syndrome Diseases 0.000 abstract description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 33
- HDWLUGYOLUHEMN-UHFFFAOYSA-N Dinobuton Chemical compound CCC(C)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1OC(=O)OC(C)C HDWLUGYOLUHEMN-UHFFFAOYSA-N 0.000 description 18
- 241000425573 Talanes Species 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 14
- 235000021590 normal diet Nutrition 0.000 description 14
- 239000000796 flavoring agent Substances 0.000 description 11
- 238000009395 breeding Methods 0.000 description 10
- 230000001488 breeding effect Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 9
- 235000013355 food flavoring agent Nutrition 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 6
- 230000003579 anti-obesity Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000004584 weight gain Effects 0.000 description 6
- 235000019786 weight gain Nutrition 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 238000005265 energy consumption Methods 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000000883 anti-obesity agent Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- -1 etc.) Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 241000220479 Acacia Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- YMKYJQIVVYKNIO-UHFFFAOYSA-N Lycopose Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(OC4C(C(O)C(OC5C(C(O)C(O)C(CO)O5)O)C(CO)O4)O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 YMKYJQIVVYKNIO-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 229940125710 antiobesity agent Drugs 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000013227 male C57BL/6J mice Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010048909 Boredom Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000021407 appetite control Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 235000013410 fast food Nutrition 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Definitions
- the present invention relates to a composition for the prevention, treatment, or improvement of obesity comprising a taxlan extract as an active ingredient.
- Obesity generally means that the body has an excessive amount of fat tissue, and the energy consumed by food is not balanced with the energy consumed by physical activity, so that surplus energy is accumulated as body fat.
- Obesity is a very diverse cause, including genetic factors, environmental factors caused by irregular eating habits, lack of exercise or excessive food intake, psychological factors caused by depression, boredom and excessive stress, and pathological factors caused by thyroid or corticosteroid changes. It is caused by the recent economic growth and lifestyle changes, many changes in eating habits, busy modern people are increasing in weight and obesity due to high calorie diet and fast exercise such as fast food.
- Obesity is perceived more seriously because of the many complications that can be caused by obesity than its own risk, and if body fat is abnormally increased due to energy imbalance over time, diabetes, hyperlipidemia, heart disease, stroke, arteriosclerosis And various metabolic diseases such as fatty liver and adult disease.
- obesity can cause mental illnesses such as social isolation, alienation, lack of confidence, and depression, obesity is a serious social problem worldwide, and the need for prevention and treatment of obesity is very important. have.
- Obesity can be treated with diet, regular exercise, lifestyle improvements such as behavioral therapy, and medications such as appetite suppressants and fat absorption inhibitors.
- Obesity is a chronic disease that requires long-term use when attempting medication.
- products approved for long-term use in Korea for more than three months include sibutramine, an appetite suppressant, and orlistat, an lipase inhibitor. There is).
- most of these anti-obesity drugs are psychotropic drugs that act on the central nervous system to control appetite, so they have side effects such as headache and vomiting and there are problems such as abuse. Therefore, there is a need for research to develop a material having high stability and excellent anti-obesity effect that can solve the side effects of the commercially available anti-obesity agents.
- Lycopus lucidus Turcz Is a perennial herbaceous plant that dried dried leaves of Lamiaceae and vegetation subfamily.
- Outposts are essential oils, glucosides, tannins, wood gin, flavonoid glycosides, phenols, amino acids, organic acids, saponins, glucose, galactose, lycopose, sucrose, raffinose, stachyose, fructose
- the fruit is composed of glucose, galactose, lycopose, sucrose, raffinose and stachyose.
- Taeglan outpost is known to exhibit a strong heart, taste is very bitter, and the properties are a little warm, it is effective to circulate blood well and to urinate well. In addition, it is known to be effective for the treatment of menstruation, jinga (duplication), postpartum ulcer pain, kidney edema, bruises, gold swelling, swelling.
- the lanthanum extract has been disclosed for the prevention or improvement of postnatal edema, but there is no disclosure about the obesity prevention, treatment, or improvement of the taxlan extract.
- the present inventors have confirmed that the lanthanum extract directly inhibits weight gain, so that it can be used as a composition for preventing, treating, or improving obesity, and preventing, treating, and preventing obesity-related complications caused by weight gain. Or it can be used for improvement purposes.
- the present inventors have tried to develop a composition for preventing or treating obesity, which has high stability and excellent anti-obesity effect, which can solve the problems of the conventional anti-obesity agent.
- the present invention was completed based on this by confirming the excellent anti-obesity effect of the taxlan extract of the present invention.
- an object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of obesity comprising a taxlan extract as an active ingredient.
- an object of the present invention is to provide a dietary supplement for the prevention or improvement of obesity comprising a taxlan extract as an active ingredient.
- the present invention provides a pharmaceutical composition for the prevention or treatment of obesity comprising a taxlan extract as an active ingredient.
- the present invention provides a dietary supplement for preventing or improving obesity comprising a taxlan extract as an active ingredient.
- the composition may inhibit the increase in weight.
- the composition may increase the rate of energy metabolism.
- the composition may inhibit the increase in blood glucose.
- the taxlan extract is extracted after adding the extraction solvent to the taxane; And lyophilizing and then extracting the extracted extract under reduced pressure. It can be prepared through.
- the extraction solvent is water, C 1 to C 4 lower alcohol, n-hexane, ethyl acetate, acetone, butyl acetate, 1,3-butylene glycol, methylene chloride, and these It may be one selected from the group consisting of a mixed solvent of.
- the present invention also provides a method for preventing or treating obesity, comprising administering the composition to a subject.
- the present invention also provides a use of the composition for the prevention or treatment of obesity.
- taxlan extract according to the present invention inhibits the increase of body weight and fasting glucose by the high fat diet in the dietary obesity-induced mouse model, increases the energy metabolic rate and improves impaired glucose tolerance. Therefore, it is expected that talan extract can be usefully used for anti-obesity functional food and drug development.
- FIG. 1 is a diagram briefly showing an experimental design using a dietary obesity-induced mouse model in order to evaluate the anti-obesity effect of the talan extract according to an embodiment of the present invention.
- Figure 2 is the normal diet group (ND), high fat diet group (HFD) according to an embodiment of the present invention by measuring the weight of the mice at a weekly interval for 4 weeks, after confirming that the obesity is well induced, high-fat diet group at 4 weeks (HFD) is divided into high-fat diet group (HFD) and talan extract feed group (LT) to measure the weight of the mice for 13 weeks to compare the weight loss and weight gain suppression effect according to the breeding period.
- ND normal diet group
- HFD high fat diet group
- LT talan extract feed group
- Figure 3 is a liver (kidney), and the normal diet group (ND), high-fat diet group (HFD) and talan extract feed group (LT) mice after breeding for 17 weeks according to an embodiment of the present invention (liver), kidney, and Figure showing the weight per 100 g body weight after the muscles (muscle) extracted and weighed.
- ND normal diet group
- HFD high-fat diet group
- LT talan extract feed group
- Figure 4 is to measure the energy consumption during the 24 hours of normal diet group (ND), high fat diet group (HFD), and talan extract feeding group (LT) mice using the animal metabolic rate measurement device to divide the energy metabolic rate into day and night To compare with quantitative values.
- ND normal diet group
- HFD high fat diet group
- LT talan extract feeding group
- FIG. 5 shows the fasting blood glucose levels of the normal diet group (ND) and the high-fat diet group (HFD) mice according to one embodiment of the present invention for 4 weeks, and then observes the fasting glucose level according to the high-fat diet.
- HFD was divided into high-fat diet (HFD) and talan extract feed (LT) to measure fasting blood glucose levels of mice at 4 week intervals for 12 weeks, and compared the changes in inhibition of fasting blood glucose increase according to breeding period.
- FIG. 6 is a glucose loading test to measure post-prandial blood sugar levels of normal diet group (ND), high fat diet group (HFD), and lanthanum extract feeding group (LT) mice according to one embodiment of the present invention.
- ND normal diet group
- HFD high fat diet group
- LT lanthanum extract feeding group mice
- the present invention provides a pharmaceutical composition for the prevention or treatment of obesity comprising a taxlan extract as an active ingredient.
- the obesity which is a disease to be prevented or treated according to the present invention, refers to a state in which fat cells proliferate and differentiate due to metabolic disorders, and thus fat is excessively accumulated, and hypertension, diabetes mellitus, and dyslipidemia Associated complications, including metabolic syndrome, may be caused.
- energy absorption increases relative to consumption, the mass and volume of fat cells increase, resulting in an increase in the mass of fat tissue.
- prevention means any action that inhibits obesity or delays the onset by administration of a pharmaceutical composition according to the invention.
- treatment refers to any action by which administration of the pharmaceutical composition according to the present invention improves or advantageously alters the symptoms of obesity.
- the "extract” is the extract itself, such as an extract obtained by the extraction process of the taxane, a diluent or concentrate of the extract, a dried product obtained by drying the extract, a modifier or purified product of the extract, or a mixture thereof. And extracts of all formulations that can be formed using extracts.
- the method for extracting the talan is not particularly limited and may be extracted according to a method commonly used in the art.
- the type of extraction solvent used to extract the taxane in the present invention is not particularly limited, and according to a conventional method known in the art for extracting the extract from natural products, that is, under the conditions of ordinary temperature, pressure It can be extracted using a phosphorus solvent.
- the taxane extract in the present invention is water, a lower alcohol having 1 to 4 carbon atoms, n-hexane, ethyl acetate, acetone, butyl acetate, 1,3-butylene glycol, methylene chloride, and a mixed solvent thereof It can be extracted using one or more solvents selected from.
- the prepared extract can then be filtered or concentrated or dried to remove the solvent, it can be carried out both filtration, concentration and drying.
- the filtration may use a filter paper or a vacuum filter
- the concentration may be a vacuum concentrator
- the drying may be a freeze-drying method, but is not limited thereto.
- mice male C57BL / 6J mice were classified into a normal diet group (ND) and a high fat diet group (HFD), and the weight was measured while breeding for 4 weeks, and the high fat diet group (HFD) was a normal diet group (ND). Obesity was induced by a sharp increase in body weight compared to). After 4 weeks, the high-fat diet group (HFD) was again classified into the high-fat diet group (HFD) and talan extract pay group (LT), and reared for 13 weeks and weighed. In the case of the high-fat diet reduced the weight gain as compared to the control as well as inhibiting the increase in weight was confirmed that the lanthanum extract is effective in weight loss (see Experimental Example 1-1 and Figure 2).
- mice in each group were bred for 17 weeks in the same manner, and sacrificed, and liver, kidney, and muscles were extracted and weighed.
- liver weight was increased and kidneys and muscles were increased. While the weight was decreased, liver weight was decreased in the taxlan extract ingestion group, and kidney and muscle weight were increased in comparison with the high fat diet group (see Experimental Examples 1-2 and FIG. 3).
- the energy metabolic rate of day and night was measured quantitatively by measuring energy consumption during 24 hours, respectively, and in the case of high-fat diet group (HFD), both day and night energy metabolic rate were significantly lower.
- HFD high-fat diet group
- LT lanthanum extract feed group
- HFD high fat diet group
- the fasting glucose level of the normal diet group (ND), high-fat diet group (HFD) mice was measured for 4 weeks, and the fasting glucose level was observed according to the high-fat diet.
- HFD normal diet group
- HFD high-fat diet group
- LT lanthanum extract group
- the experimental results of the present invention showed that the lanthanum extract has the effect of inhibiting the increase in body weight and fasting blood glucose, the increase in energy metabolic rate and impaired glucose tolerance.
- the "pharmaceutical composition” in the present invention means that is prepared for the purpose of preventing or treating a disease, each can be used in formulated in various forms according to conventional methods.
- it may be formulated in oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, and syrups, and may be formulated in the form of external preparations, suppositories, and sterile injectable solutions.
- the pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier in addition to the active ingredient.
- the pharmaceutically acceptable carrier is commonly used in the preparation, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose , Polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil, and the like.
- it may further include a lubricant, wetting agent, sweetener, flavoring agent, emulsifier, suspending agent, preservative and the like.
- compositions of the present invention can be administered orally or parenterally (eg, applied intravenously, subcutaneously, intraperitoneally or topically) according to the desired method, and the dosage is determined by the condition and weight of the patient, Depending on the extent, drug form, route of administration, and time, it may be appropriately selected by those skilled in the art.
- the pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.
- pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level refers to the type of disease, the severity, the activity of the drug, It may be determined according to the sensitivity to the drug, the time of administration, the route of administration and the rate of release, the duration of treatment, factors including the drug used concurrently and other factors well known in the medical field.
- the pharmaceutical compositions according to the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered as single or multiple doses. Taking all of the above factors into consideration, it is important to administer an amount that can achieve the maximum effect with a minimum amount without side effects, which can be readily determined by one skilled in the art.
- the present invention provides a dietary supplement for preventing or improving obesity comprising a taxlan extract.
- the term “improvement” refers to any action that at least reduces the parameters associated with the condition being treated, for example the extent of symptoms.
- the health functional food composition may be used simultaneously or separately with the agent for treatment before or after the onset of the disease for the prevention or improvement of obesity.
- the "health food composition” is characterized in that it is formulated as one selected from the group consisting of tablets, pills, powders, granules, powders, capsules and liquid formulations, including one or more of carriers, diluents, excipients and additives. It is done.
- Foods that can be added to the extract of the present invention include various foods, powders, granules, tablets, capsules, syrups, beverages, gums, teas, vitamin complexes, and health functional foods.
- additives which may be further included in the present invention, natural carbohydrates, flavoring agents, nutrients, vitamins, minerals (electrolytes), flavoring agents (synthetic flavoring agents, natural flavoring agents, etc.), colorants, fillers, pactic acid and salts thereof, Alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, antioxidants, glycerin, alcohols, carbonation agents, and one or more components selected from the group consisting of pulp can be used.
- natural carbohydrates examples include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
- natural flavoring agents tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used.
- composition according to the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and neutralizing agents, fact acids and salts thereof, alginic acid and salts thereof, organic acids, protection Sex colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages and the like.
- compositions of the present invention may contain pulp for the production of natural fruit juices and vegetable beverages. These components can be used independently or in combination.
- carrier examples include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, erythritol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium phosphate, calcium silicate, Group consisting of microcrystalline cellulose, polyvinylchirrolidone, cellulose, polyvinylpyrrolidone, methylcellulose, water, sugar syrup, methyl hydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate, and mineral oil It is preferred that at least one selected from be used.
- the extract was pressurized at 105 ° C. for 5 hours, and the extraction frequency was twice. After extraction, the extract was concentrated under reduced pressure, and then freeze-dried to prepare a lanthanum extract. The yield of the lanthanum extract was calculated to be 15.44%.
- mice of each group bred for 17 weeks by the method of Experimental Example 1-1 were fasted for 12 hours, anesthetized through inhalation of isoflurane (isoflurane) (Baxter, USA), and sacrificed and organs were extracted. . Liver, kidney, and muscle tissues of each mouse were rinsed several times with phosphate buffered saline (PBS), drained, weighed, and expressed as weight per 100 g of body weight.
- PBS phosphate buffered saline
- the liver tissue significantly increased the weight of the high-fat diet group (HFD) compared to the normal diet group (ND), the weight of the lanthanum extract supplement group (LT) significantly reduced liver weight It was.
- the height and muscle weight per unit weight was significantly decreased in the high-fat diet group compared to the normal diet group, and the height and muscle weight of the taxlan extract supplement group was significantly increased compared to the high-fat diet group. Therefore, it was confirmed through the above results that the lanthanum extract reduces the weight of liver and increases the weight of kidney and muscle.
- the purpose of this study was to determine whether taxane extract intake affects energy expenditure (EE) as well as body weight and hypoglycemic effects.
- EE energy expenditure
- the energy consumption of the mouse was measured using the animal metabolic rate measuring device (Oxylet; Panlab, Cornella, Spain) at 14 weeks of breeding the mouse by the method of Experimental Example 1-1. More specifically, after calibrating the measuring device with oxygen and carbon, the flow rate in the cage was adjusted to 3 L / min. Thereafter, each mouse was placed in a separate metabolic cage, and the energy consumption for 24 hours was measured. Subsequently, the energy consumption was derived by substituting Equation 1 below.
- mice were fasted for 12 hours during the four-week breeding period by the method of Experimental Example 1-1, and blood glucose levels were measured by fasting blood glucose by measuring blood fastening by tailing.
- Fasting group was divided into high-fat diet group (HFD) and talan extract feed group (LT), and fasting blood glucose was measured in the same manner as above during the 12-week breeding period.
- the high-fat diet group maintained a significantly increased blood sugar level compared to the normal diet group (ND), while the lanthanum extract supplement group (LT) for 12 weeks. It was confirmed that the high-fat diet maintained lower blood sugar levels than the group fed throughout the breeding period. Through the above results, it was found that the taxlan extract has an excellent hypoglycemic effect.
- mice After the meal, the mice were fasted for 12 hours at week 16 when the mice were bred by the method of Experimental Example 1-1 to measure the change in blood glucose concentration after the administration of glucose solution intraperitoneally by 0.5 g / kg body weight, respectively, 0, 30, Blood glucose was measured by blood collection through the tail vein at 60 and 120 minutes. Blood glucose measurement The blood glucose concentration of each time period was represented based on the blood glucose concentration of 100 minutes.
- the blood sugar of all the experimental group showed a peak after 30 minutes of glucose load gradually decreased after 60 minutes, the blood sugar of the lanthanide extract feeding group (LT) at all time periods (HFD)
- the blood sugar level after 120 minutes was significantly lower than that of the high-fat diet group (HFD). From the above, it was confirmed that when dietary supplementation of lanthanum extract significantly improved postprandial blood sugar due to high fat diet, thereby improving glucose tolerance.
- composition comprising the taxane extract according to the present invention as an active ingredient may be usefully used for the prevention, treatment, or improvement of obesity-related complications that can be caused by weight gain as well as obesity.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a composition containing a Lycopus lucidus Turcz. extract as an active ingredient for prevention, treatment, or alleviation of obesity. It was confirmed that the Lycopus lucidus Turcz. extract according to the present invention had effects of suppressing a body weight increase and a fasting blood sugar level increase caused by a high-fat diet, increasing an energy metabolic rate, and alleviating impaired glucose tolerance in dietary obesity-induced mouse models. Therefore, the Lycopus lucidus Turcz. extract can be advantageously used for prevention, treatment, or alleviation of obesity as well as obesity-related complications that may be caused by weight increase.
Description
본 발명은 택란추출물을 유효성분으로 포함하는 비만 예방, 치료, 또는 개선용 조성물 등에 관한 것이다.The present invention relates to a composition for the prevention, treatment, or improvement of obesity comprising a taxlan extract as an active ingredient.
비만은 일반적으로 체내에 지방조직이 과다한 상태인 것을 의미하며, 음식물로 섭취한 에너지가 신체활동 등으로 소비한 에너지와 균형을 이루지 못하여 잉여의 에너지가 체지방으로 축적되는 현상이다. 비만은 유전적인 요인, 불규칙한 식습관이나 운동부족 또는 패스트푸드의 과다섭취 등에 의한 환경적 요인, 우울감, 지루감, 과다한 스트레스 등에 의한 심리적 요인, 갑상선이나 부신피질 호르몬 변화에 의한 병적인 요인 등 매우 다양한 원인에 의해 발생하는데, 최근 경제성장과 생활방식의 변화에 따라 식습관에도 많은 변화가 생겨 바쁜 현대인들은 패스트푸드 등의 고열량 식이와 적은 운동량으로 인하여 체중 및 비만이 증가하고 있는 추세이다.Obesity generally means that the body has an excessive amount of fat tissue, and the energy consumed by food is not balanced with the energy consumed by physical activity, so that surplus energy is accumulated as body fat. Obesity is a very diverse cause, including genetic factors, environmental factors caused by irregular eating habits, lack of exercise or excessive food intake, psychological factors caused by depression, boredom and excessive stress, and pathological factors caused by thyroid or corticosteroid changes. It is caused by the recent economic growth and lifestyle changes, many changes in eating habits, busy modern people are increasing in weight and obesity due to high calorie diet and fast exercise such as fast food.
비만은 그 자체의 위험성보다 비만으로 인해 유발될 수 있는 여러 합병증 때문에 그 심각성이 더욱 크게 인식되고 있으며, 오랜 시간에 걸쳐 에너지 불균형에 의해 체지방이 비정상적으로 많아지면 당뇨, 고지혈증, 심장병, 뇌졸중, 동맥경화증, 지방간 등의 각종 대사성 질환과 성인병이 유발된다. 또한, 비만에 의해 사회적 고립감이나 소외, 자신감 결여, 우울감과 같은 정신적 질환이 유발될 수 있으므로, 비만은 전 세계적으로 심각한 사회문제로 대두되고 있으며 비만의 예방 및 치료에 대한 필요성이 매우 중요하게 인식되고 있다. Obesity is perceived more seriously because of the many complications that can be caused by obesity than its own risk, and if body fat is abnormally increased due to energy imbalance over time, diabetes, hyperlipidemia, heart disease, stroke, arteriosclerosis And various metabolic diseases such as fatty liver and adult disease. In addition, since obesity can cause mental illnesses such as social isolation, alienation, lack of confidence, and depression, obesity is a serious social problem worldwide, and the need for prevention and treatment of obesity is very important. have.
비만은 식이요법, 규칙적인 운동과 더불어 행동요법과 같은 생활습관의 개선, 및 식욕 억제제와 지방 흡수 억제제와 같은 약물을 통해 치료할 수 있다. 비만은 만성 질환이기 때문에 약물치료를 시도하는 경우 장기간의 사용이 필요하며, 현재 국내에서 3개월 이상 장기간 사용이 허가된 제품으로는 식욕억제제인 시부트라민(sibutramine)과 지방분해효소 억제제인 올리스타트(orlistat)가 있다. 그러나 이러한 비만 치료 약물들은 대부분 중추신경계에 작용하여 식욕을 조절하는 향정신성의약품들이므로 두통 및 구토 등의 부작용을 동반하며 남용 우려 등의 문제점이 있다. 따라서 상기 시판중인 항비만제의 부작용을 해결할 수 있는 안정성이 높고 항비만 효과가 우수한 소재를 개발하기 위한 연구가 필요한 실정이다.Obesity can be treated with diet, regular exercise, lifestyle improvements such as behavioral therapy, and medications such as appetite suppressants and fat absorption inhibitors. Obesity is a chronic disease that requires long-term use when attempting medication. Currently, products approved for long-term use in Korea for more than three months include sibutramine, an appetite suppressant, and orlistat, an lipase inhibitor. There is). However, most of these anti-obesity drugs are psychotropic drugs that act on the central nervous system to control appetite, so they have side effects such as headache and vomiting and there are problems such as abuse. Therefore, there is a need for research to develop a material having high stability and excellent anti-obesity effect that can solve the side effects of the commercially available anti-obesity agents.
한편, 택란(Lycopus lucidus Turcz.)은 다년생 초본식물로서 꿀풀과 식물 지과아묘의 경엽을 건조한 것이다. 전초는 정유, 글루코시드, 탄닌, 나무진, 플라보노이드 배당체, 페놀류, 아미노산, 유기산, 사포닌, 포도당, 갈락토오스, 리코포스(lycopose), 수크로스(sucrose), 라피노스(raffinose), 스타키오스 (stachyose), 과당 등으로 구성되어 있으며 과실은 포도당, 갈락토오스, 리코포스(lycopose), 수크로스 (sucrose), 라피노스(raffinose), 스타키오스(stachyose) 등이 주성분을 이루고 있다. On the other hand, Lycopus lucidus Turcz. Is a perennial herbaceous plant that dried dried leaves of Lamiaceae and vegetation subfamily. Outposts are essential oils, glucosides, tannins, wood gin, flavonoid glycosides, phenols, amino acids, organic acids, saponins, glucose, galactose, lycopose, sucrose, raffinose, stachyose, fructose The fruit is composed of glucose, galactose, lycopose, sucrose, raffinose and stachyose.
택란의 전초는 강심작용을 나타내는 것으로 알려져 있으며 맛은 쓰고 매우며 성질은 약간 온한데 혈을 잘 순환하게 하고 소변이 잘 나오게 하는 효능이 있다. 또한, 월경폐지, 징가(복중 경결), 산후 울체복통, 신면부종, 타박상, 금창, 부스럼 등의 치료에 효과가 있는 것으로 알려져 있다.Taeglan outpost is known to exhibit a strong heart, taste is very bitter, and the properties are a little warm, it is effective to circulate blood well and to urinate well. In addition, it is known to be effective for the treatment of menstruation, jinga (duplication), postpartum ulcer pain, kidney edema, bruises, gold swelling, swelling.
종래에 택란추출물의 산전산후부종 예방 또는 개선 효과에 대해서 공개된 바가 있으나, 택란추출물의 비만 예방, 치료, 또는 개선 효과에 대해서는 공개된 바가 없다.Conventionally, the lanthanum extract has been disclosed for the prevention or improvement of postnatal edema, but there is no disclosure about the obesity prevention, treatment, or improvement of the taxlan extract.
이에, 본 발명자들은 택란추출물이 체중 증가를 직접적으로 억제하는 것을 확인하여, 비만의 예방, 치료, 또는 개선용 조성물로 이용될 수 있도록 하였으며, 체중 증가에 따라 유발되는 비만 관련 합병증의 예방, 치료, 또는 개선 용도로도 이용될 수 있도록 하였다. Thus, the present inventors have confirmed that the lanthanum extract directly inhibits weight gain, so that it can be used as a composition for preventing, treating, or improving obesity, and preventing, treating, and preventing obesity-related complications caused by weight gain. Or it can be used for improvement purposes.
본 발명자들은 종래 항비만제의 문제점을 해결할 수 있는 안정성이 높고 항비만 효과가 우수한 비만 예방 또는 치료용 조성물을 개발하고자 노력한 결과, 고지방식이에 의해 비만이 유도된 마우스 모델에서 택란추출물을 고지방식이에 혼합하여 급여시키며 관찰한 결과, 본 발명의 택란추출물의 우수한 항비만 효과를 확인함으로써 이에 기초하여 본 발명을 완성하였다.The present inventors have tried to develop a composition for preventing or treating obesity, which has high stability and excellent anti-obesity effect, which can solve the problems of the conventional anti-obesity agent. As a result of mixing and observing the result, the present invention was completed based on this by confirming the excellent anti-obesity effect of the taxlan extract of the present invention.
이에, 본 발명은 택란추출물을 유효성분으로 포함하는 비만 예방 또는 치료용 약학적 조성물을 제공하는 것을 목적으로 한다.Accordingly, an object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of obesity comprising a taxlan extract as an active ingredient.
또한, 본 발명은 택란추출물을 유효성분으로 포함하는 비만 예방 또는 개선용 건강기능식품 조성물을 제공하는 것을 목적으로 한다. In addition, an object of the present invention is to provide a dietary supplement for the prevention or improvement of obesity comprising a taxlan extract as an active ingredient.
그러나 본 발명이 이루고자 하는 기술적 과제는 이상에서 언급한 과제에 제한되지 않으며, 언급되지 않은 또 다른 과제들은 아래의 기재로부터 당해 기술분야의 통상의 기술자에게 명확하게 이해될 수 있을 것이다.However, the technical problem to be achieved by the present invention is not limited to the above-mentioned problem, another task that is not mentioned will be clearly understood by those skilled in the art from the following description.
상기와 같은 목적을 달성하기 위하여, 본 발명은 택란추출물을 유효성분으로 포함하는 비만 예방 또는 치료용 약학적 조성물을 제공한다.In order to achieve the above object, the present invention provides a pharmaceutical composition for the prevention or treatment of obesity comprising a taxlan extract as an active ingredient.
또한, 본 발명은 택란추출물을 유효성분으로 포함하는 비만 예방 또는 개선용 건강기능식품 조성물을 제공한다.In addition, the present invention provides a dietary supplement for preventing or improving obesity comprising a taxlan extract as an active ingredient.
본 발명의 일구현예로서, 상기 조성물은 체중의 증가를 억제시킬 수 있다.In one embodiment of the invention, the composition may inhibit the increase in weight.
본 발명의 다른 일구현예로서, 상기 조성물은 에너지 대사율을 증가시킬 수 있다.In another embodiment of the present invention, the composition may increase the rate of energy metabolism.
본 발명의 또 다른 일구현예로서, 상기 조성물은 혈당 증가를 억제시킬 수 있다.In another embodiment of the present invention, the composition may inhibit the increase in blood glucose.
본 발명의 또 다른 일구현예로서, 상기 택란추출물은 택란에 추출용매를 첨가한 후 추출하는 단계; 및 추출된 추출물을 감압농축한 후 동결건조 하는 단계; 를 통해 제조될 수 있다.As another embodiment of the present invention, the taxlan extract is extracted after adding the extraction solvent to the taxane; And lyophilizing and then extracting the extracted extract under reduced pressure. It can be prepared through.
본 발명의 또 다른 일구현예로서, 상기 추출용매는 물, C1내지 C4의 저급알코올, n-헥산, 에틸아세테이트, 아세톤, 부틸아세테이트, 1,3-부틸렌 글리콜, 메틸렌클로라이드, 및 이들의 혼합용매로 구성된 군으로부터 선택된 1종일 수 있다.As another embodiment of the present invention, the extraction solvent is water, C 1 to C 4 lower alcohol, n-hexane, ethyl acetate, acetone, butyl acetate, 1,3-butylene glycol, methylene chloride, and these It may be one selected from the group consisting of a mixed solvent of.
또한, 본 발명은 상기 조성물을 개체에 투여하는 단계를 포함하는, 비만 예방 또는 치료 방법을 제공한다.The present invention also provides a method for preventing or treating obesity, comprising administering the composition to a subject.
또한, 본 발명은 상기 조성물의 비만 예방 또는 치료 용도를 제공한다.The present invention also provides a use of the composition for the prevention or treatment of obesity.
본 발명에 따른 택란추출물은 식이성 비만 유도 마우스 모델에서 고지방식이에 의한 체중 및 공복혈당의 증가를 억제시키며, 에너지 대사율을 증가시키고 내당능 장애를 개선시키는 효과가 있음을 확인하였다. 따라서 택란추출물은 항비만 관련 기능성 식품 및 의약품 개발 등에 유용하게 이용될 수 있을 것으로 기대된다.It was confirmed that the taxlan extract according to the present invention inhibits the increase of body weight and fasting glucose by the high fat diet in the dietary obesity-induced mouse model, increases the energy metabolic rate and improves impaired glucose tolerance. Therefore, it is expected that talan extract can be usefully used for anti-obesity functional food and drug development.
도 1은 본 발명의 일구현예에 따른 택란추출물의 항비만 효과를 평가하기 위하여 식이성 비만 유도 마우스 모델을 이용한 실험 디자인을 간략하게 나타낸 도면이다. 1 is a diagram briefly showing an experimental design using a dietary obesity-induced mouse model in order to evaluate the anti-obesity effect of the talan extract according to an embodiment of the present invention.
도 2는 본 발명의 일구현예에 따른 정상식이군(ND), 고지방식이군(HFD) 마우스들의 체중을 4주 동안 일주일 간격으로 측정하여 비만이 잘 유도되었는지를 확인한 후, 4주차에 고지방식이군(HFD)을 다시 고지방식이군(HFD) 및 택란추출물 급여군(LT)으로 나누어 13주 동안 마우스들의 체중을 측정하여 사육기간에 따른 체중감소 및 체중증가 억제 효능을 비교하여 나타낸 도면이다. Figure 2 is the normal diet group (ND), high fat diet group (HFD) according to an embodiment of the present invention by measuring the weight of the mice at a weekly interval for 4 weeks, after confirming that the obesity is well induced, high-fat diet group at 4 weeks (HFD) is divided into high-fat diet group (HFD) and talan extract feed group (LT) to measure the weight of the mice for 13 weeks to compare the weight loss and weight gain suppression effect according to the breeding period.
도 3은 본 발명의 일구현예에 따른 정상식이군(ND), 고지방식이군(HFD) 및 택란추출물 급여군(LT) 마우스들을 17주 동안 사육한 후 간(liver), 신장(kidney), 및 근육(muscle)을 적출하고 중량을 측정한 후 체중 100 g 당 중량으로 나타낸 도면이다. Figure 3 is a liver (kidney), and the normal diet group (ND), high-fat diet group (HFD) and talan extract feed group (LT) mice after breeding for 17 weeks according to an embodiment of the present invention (liver), kidney, and Figure showing the weight per 100 g body weight after the muscles (muscle) extracted and weighed.
도 4는 동물대사율 측정 장치를 이용하여 정상식이군(ND), 고지방식이군(HFD), 및 택란추출물 급여군(LT) 마우스들의 24시간 동안의 에너지 소비량을 측정하여 에너지 대사율을 낮과 밤으로 구분하여 정량적인 값으로 비교하여 나타낸 도면이다.Figure 4 is to measure the energy consumption during the 24 hours of normal diet group (ND), high fat diet group (HFD), and talan extract feeding group (LT) mice using the animal metabolic rate measurement device to divide the energy metabolic rate into day and night To compare with quantitative values.
도 5는 본 발명의 일구현예에 따른 정상식이군(ND), 고지방식이군(HFD) 마우스들의 공복혈당을 4주 동안 측정하여 고지방식이에 따른 공복혈당 증가를 관찰한 후, 4주차에 고지방식이군(HFD)을 다시 고지방식이군(HFD) 및 택란추출물 급여군(LT)으로 나누어 12주 동안 4주일 간격으로 마우스들의 공복 혈당을 측정하여 사육기간에 따른 공복혈당 증가 억제 변화를 비교하여 나타낸 도면이다.FIG. 5 shows the fasting blood glucose levels of the normal diet group (ND) and the high-fat diet group (HFD) mice according to one embodiment of the present invention for 4 weeks, and then observes the fasting glucose level according to the high-fat diet. HFD was divided into high-fat diet (HFD) and talan extract feed (LT) to measure fasting blood glucose levels of mice at 4 week intervals for 12 weeks, and compared the changes in inhibition of fasting blood glucose increase according to breeding period. Drawing.
도 6은 본 발명의 일구현예에 따른 정상식이군(ND), 고지방식이군(HFD), 및 택란추출물 급여군(LT) 마우스들의 식후 혈당농도 변화를 측정하고자 당부하 검사를 실시하여, 혈당 측정 0분의 혈당 농도를 100으로 기준하여 각 시간대별 혈당 농도를 보여주는 결과를 나타낸 도면이다. FIG. 6 is a glucose loading test to measure post-prandial blood sugar levels of normal diet group (ND), high fat diet group (HFD), and lanthanum extract feeding group (LT) mice according to one embodiment of the present invention. A diagram showing a result showing blood sugar concentrations for each time slot based on a blood sugar concentration of 100 for 0 minutes.
본 발명은 다양한 변환을 가할 수 있고 여러 가지 실시예를 가질 수 있는 바, 특정 실시예들을 도면에 예시하고 상세한 설명에 상세하게 설명하고자 한다. 그러나, 이는 본 발명을 특정한 실시 형태에 대해 한정하려는 것이 아니며, 본 발명의 사상 및 기술 범위에 포함되는 모든 변환, 균등물 내지 대체물을 포함하는 것으로 이해되어야 한다. 본 발명을 설명함에 있어서 관련된 공지 기술에 대한 구체적인 설명이 본 발명의 요지를 흐릴 수 있다고 판단되는 경우 그 상세한 설명을 생략한다.As the invention allows for various changes and numerous embodiments, particular embodiments will be illustrated in the drawings and described in detail in the written description. However, this is not intended to limit the present invention to specific embodiments, it should be understood to include all transformations, equivalents, and substitutes included in the spirit and scope of the present invention. In the following description of the present invention, if it is determined that the detailed description of the related known technology may obscure the gist of the present invention, the detailed description thereof will be omitted.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 택란추출물을 유효성분으로 포함하는 비만 예방 또는 치료용 약학적 조성물을 제공한다.The present invention provides a pharmaceutical composition for the prevention or treatment of obesity comprising a taxlan extract as an active ingredient.
본 발명의 예방 또는 치료 대상 질병인 "비만(obesity)"은, 대사 장애로 인하여 체내에 지방세포가 증식 분화하고 이로 인하여 지방이 과잉으로 축적된 상태를 의미하며, 고혈압, 당뇨, 및 이상지질혈증 등을 동반하는 대사증후군을 포함하는 관련 합병증을 유발할 수 있다. 에너지 흡수량이 소비량에 비해 상대적으로 증가하는 경우, 지방세포의 수와 부피가 증가되는 과정을 거쳐 결과적으로 지방조직의 질량이 증가된다.The obesity, which is a disease to be prevented or treated according to the present invention, refers to a state in which fat cells proliferate and differentiate due to metabolic disorders, and thus fat is excessively accumulated, and hypertension, diabetes mellitus, and dyslipidemia Associated complications, including metabolic syndrome, may be caused. When energy absorption increases relative to consumption, the mass and volume of fat cells increase, resulting in an increase in the mass of fat tissue.
본 발명에서 사용되는 용어 "예방"은, 본 발명에 따른 약학적 조성물의 투여에 의해 비만을 억제시키거나 발병을 지연시키는 모든 행위를 의미한다.As used herein, the term "prevention" means any action that inhibits obesity or delays the onset by administration of a pharmaceutical composition according to the invention.
본 발명에서 사용되는 용어 "치료"는, 본 발명에 따른 약학적 조성물의 투여에 의해 비만에 대한 증세가 호전되거나 이롭게 변경되는 모든 행위를 의미한다.As used herein, the term "treatment" refers to any action by which administration of the pharmaceutical composition according to the present invention improves or advantageously alters the symptoms of obesity.
본 발명에서 "추출물"은, 상기 택란의 추출처리에 의하여 얻어지는 추출액, 상기 추출액의 희석액이나 농축액, 상기 추출액을 건조하여 얻어지는 건조물, 상기 추출액의 조정제물이나 정제물, 또는 이들의 혼합물 등, 추출액 자체 및 추출액을 이용하여 형성 가능한 모든 제형의 추출물을 포함한다.In the present invention, the "extract" is the extract itself, such as an extract obtained by the extraction process of the taxane, a diluent or concentrate of the extract, a dried product obtained by drying the extract, a modifier or purified product of the extract, or a mixture thereof. And extracts of all formulations that can be formed using extracts.
본 발명의 상기 택란추출물에 있어서, 상기 택란을 추출하는 방법은 특별히 제한되지 아니하며, 당해 기술분야에서 통상적으로 사용하는 방법에 따라 추출할 수 있다. 상기 추출 방법의 비제한적인 예로는, 열수 추출법, 초음파 추출법, 여과법, 환류 추출법 등을 들 수 있으며, 이들은 단독으로 수행되거나 2 종 이상의 방법을 병용하여 수행될 수 있다. In the talan extract of the present invention, the method for extracting the talan is not particularly limited and may be extracted according to a method commonly used in the art. Non-limiting examples of the extraction method, hot water extraction method, ultrasonic extraction method, filtration method, reflux extraction method and the like, these may be carried out alone or in combination of two or more methods.
본 발명에서 상기 택란을 추출하는 데에 사용되는 추출 용매의 종류는 특별히 제한되지 아니하며, 천연물로부터 추출물을 추출하는 당업계에 공지된 통상적인 방법에 따라, 즉, 통상적인 온도, 압력의 조건 하에서 통상적인 용매를 사용하여 추출할 수 있다. 예컨대, 본 발명에서 택란추출물은 물, 탄소 수 1 내지 4의 저급 알코올, n-헥산, 에틸아세테이트, 아세톤, 부틸아세테이트, 1,3-부틸렌 글리콜, 메틸렌클로라이드, 및 이들의 혼합 용매로 이루어진 군으로부터 선택된 1종 이상의 용매를 사용하여 추출할 수 있다. The type of extraction solvent used to extract the taxane in the present invention is not particularly limited, and according to a conventional method known in the art for extracting the extract from natural products, that is, under the conditions of ordinary temperature, pressure It can be extracted using a phosphorus solvent. For example, the taxane extract in the present invention is water, a lower alcohol having 1 to 4 carbon atoms, n-hexane, ethyl acetate, acetone, butyl acetate, 1,3-butylene glycol, methylene chloride, and a mixed solvent thereof It can be extracted using one or more solvents selected from.
상기 제조된 추출물은 이후 여과하거나 농축 또는 건조과정을 수행하여 용매를 제거할 수 있으며, 여과, 농축 및 건조를 모두 수행할 수 있다. 예컨대, 여과는 여과지를 이용하거나 감압여과기를 이용할 수 있으며, 농축은 감압 농축기, 건조는 동결건조법 등을 수행할 수 있으나, 이에 제한되는 것은 아니다.The prepared extract can then be filtered or concentrated or dried to remove the solvent, it can be carried out both filtration, concentration and drying. For example, the filtration may use a filter paper or a vacuum filter, the concentration may be a vacuum concentrator, the drying may be a freeze-drying method, but is not limited thereto.
본 발명의 일실험예에서는 상기 방법으로 추출한 택란추출물의 항비만 효과를 평가하기 위하여, 식이성 비만 유도 마우스 모델을 이용하여 실험을 진행하였다.In one experimental example of the present invention, in order to evaluate the anti-obesity effect of the talan extract extracted by the above method, an experiment was conducted using a dietary obesity-induced mouse model.
본 발명의 일실험예에서는, 수컷 C57BL/6J 마우스를 정상식이군(ND) 및 고지방식이군(HFD)으로 분류하여 4주 동안 사육하면서 체중을 측정한 결과 고지방식이군(HFD)이 정상식이군(ND)에 비해 체중이 급격히 증가하여 비만이 유도된 것을 관찰하였다. 이 후, 4주차 시점에서 고지방식이군(HFD)을 다시 고지방식이군(HFD) 및 택란추출물 급여군(LT)으로 분류하여 13주 동안 사육하며 체중을 측정한 결과, 택란추출물 급여군(LT)의 경우 고지방식이 대조군에 비해 증가된 체중을 감소시켰을 뿐만 아니라 체중증가를 억제하는 것을 관찰함으로써 택란추출물이 체중 감량에 효과가 있음을 확인하였다(실험예 1-1 및 도 2 참조).In one experimental example of the present invention, male C57BL / 6J mice were classified into a normal diet group (ND) and a high fat diet group (HFD), and the weight was measured while breeding for 4 weeks, and the high fat diet group (HFD) was a normal diet group (ND). Obesity was induced by a sharp increase in body weight compared to). After 4 weeks, the high-fat diet group (HFD) was again classified into the high-fat diet group (HFD) and talan extract pay group (LT), and reared for 13 weeks and weighed. In the case of the high-fat diet reduced the weight gain as compared to the control as well as inhibiting the increase in weight was confirmed that the lanthanum extract is effective in weight loss (see Experimental Example 1-1 and Figure 2).
또한, 상기 각 군의 마우스들을 동일한 방법으로 총 17주 동안 사육시킨 후 희생시켜 간, 신장, 및 근육을 적출하여 중량을 측정한 결과 고지방식이군(HFD)의 경우 간 중량이 증가하고 신장과 근육 중량이 감소한 반면, 택란추출물 섭취군에서는 고지방식이군에 비하여 간중량이 감소하였고, 신장과 근육 중량은 증가하였다(실험예 1-2 및 도 3 참조).In addition, mice in each group were bred for 17 weeks in the same manner, and sacrificed, and liver, kidney, and muscles were extracted and weighed. As a result, in the high-fat diet group (HFD), liver weight was increased and kidneys and muscles were increased. While the weight was decreased, liver weight was decreased in the taxlan extract ingestion group, and kidney and muscle weight were increased in comparison with the high fat diet group (see Experimental Examples 1-2 and FIG. 3).
본 발명의 다른 실험예에서는, 24시간 동안의 에너지 소비량을 측정하여 낮과 밤의 에너지 대사율을 각각 정량적으로 비교한 결과 고지방식이군(HFD)의 경우 낮과 밤의 에너지 대사율이 모두 유의적으로 낮은 반면 택란추출물 급여군(LT)에서는 낮시간대에 고지방식이군(HFD)에 비해 유의적으로 증가함을 확인하였다(실험예 2 및 도 4 참조). In another experimental example of the present invention, the energy metabolic rate of day and night was measured quantitatively by measuring energy consumption during 24 hours, respectively, and in the case of high-fat diet group (HFD), both day and night energy metabolic rate were significantly lower. On the other hand, it was confirmed that the lanthanum extract feed group (LT) increased significantly compared to the high fat diet group (HFD) during the day time (see Experimental Example 2 and FIG. 4).
본 발명의 또 다른 실험예에서는, 정상식이군(ND), 고지방식이군(HFD) 마우스들의 공복혈당을 4주 동안 측정하여 고지방식이에 따른 공복혈당증가를 관찰한 후, 4주차에 고지방식이군(HFD)을 다시 고지방식이군 및 택란추출물 급여군(LT)으로 나누어 12주 동안 4주일 간격으로 마우스들의 공복 혈당을 측정하여 사육기간에 따른 공복혈당 증가 억제 변화를 비교한 결과 택란추출물 급여군(LT)의 경우 고지방식이군(HFD)에 비해 공복혈당 증가를 억제시키는 것을 확인하였다(실험예 3 및 도 5 참조).In another experimental example of the present invention, the fasting glucose level of the normal diet group (ND), high-fat diet group (HFD) mice was measured for 4 weeks, and the fasting glucose level was observed according to the high-fat diet. (HFD) was divided into high-fat diet and lanthanum extract group (LT), and fasting blood glucose levels of mice were measured every four weeks for 12 weeks. LT) was confirmed to suppress the fasting blood glucose increase compared to the high fat diet group (HFD) (see Experimental Example 3 and Figure 5).
본 발명의 또 다른 실험예에서는, 상기 각 마우스 군에서 복강 내 포도당 투여 후 혈당 농도 변화를 분석한 결과 택란추출물 급여군(LT)의 경우 내당능이 증가하여, 내당능 장애를 개선시킬 수 있음을 확인하였다(실험예 4 및 도 6 참조).In another experimental example of the present invention, as a result of analyzing the blood glucose concentration change after intraperitoneal glucose administration in each mouse group, it was confirmed that the glulan extract feeding group (LT) increased glucose tolerance, thereby improving impaired glucose tolerance. (See Experimental Example 4 and FIG. 6).
따라서, 본 발명의 실험예 결과를 통하여 택란추출물이 체중 및 공복혈당 증가 억제 효과, 에너지 대사율 증가 및 내당능 장애 개선 효과를 가지는 것을 알 수 있었다.Therefore, the experimental results of the present invention showed that the lanthanum extract has the effect of inhibiting the increase in body weight and fasting blood glucose, the increase in energy metabolic rate and impaired glucose tolerance.
한편, 본 발명에서 "약학적 조성물"은 질병의 예방 또는 치료를 목적으로 제조된 것을 의미하며, 각각 통상의 방법에 따라 다양한 형태로 제형화하여 사용될 수 있다. 예컨대, 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽 등의 경구형 제형으로 제형화할 수 있고, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용할 수 있다. On the other hand, the "pharmaceutical composition" in the present invention means that is prepared for the purpose of preventing or treating a disease, each can be used in formulated in various forms according to conventional methods. For example, it may be formulated in oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, and syrups, and may be formulated in the form of external preparations, suppositories, and sterile injectable solutions.
또한, 본 발명의 약학적 조성물은 유효성분 이외에 약학적으로 허용되는 담체를 포함할 수 있다. 이때, 약제학적으로 허용되는 담체는 제제 시에 통상적으로 이용되는 것으로서, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아고무, 인산칼슘, 알기네이트, 젤라틴, 규산칼슘, 미세결정성 셀룰로스, 폴리비닐피로리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필 히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. 또한, 상기성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다.In addition, the pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier in addition to the active ingredient. At this time, the pharmaceutically acceptable carrier is commonly used in the preparation, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose , Polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil, and the like. In addition to the above components, it may further include a lubricant, wetting agent, sweetener, flavoring agent, emulsifier, suspending agent, preservative and the like.
본 발명의 약학적 조성물은 목적하는 방법에 따라 경구 투여하거나 비경구투여(예를 들어, 정맥 내, 피하, 복강 내 또는 국소에 적용)할 수 있으며, 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 시간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다.The pharmaceutical compositions of the present invention can be administered orally or parenterally (eg, applied intravenously, subcutaneously, intraperitoneally or topically) according to the desired method, and the dosage is determined by the condition and weight of the patient, Depending on the extent, drug form, route of administration, and time, it may be appropriately selected by those skilled in the art.
본 발명의 약학적 조성물은 약학적으로 유효한 양으로 투여한다. 본 발명에 있어서 "약학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효용량 수준은 환자의 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출비율, 치료기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명에 따른 약학적 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래의 치료제와는 순차적 또는 동시에 투여될 수 있으며, 단일 또는 다중 투여될 수 있다. 상기 요소들을 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 이는 당업자에 의해 용이하게 결정될 수 있다.The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. As used herein, the term “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level refers to the type of disease, the severity, the activity of the drug, It may be determined according to the sensitivity to the drug, the time of administration, the route of administration and the rate of release, the duration of treatment, factors including the drug used concurrently and other factors well known in the medical field. The pharmaceutical compositions according to the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered as single or multiple doses. Taking all of the above factors into consideration, it is important to administer an amount that can achieve the maximum effect with a minimum amount without side effects, which can be readily determined by one skilled in the art.
또한, 본 발명은 택란추출물을 포함하는 비만 예방 또는 개선용 건강기능식품 조성물을 제공한다. In addition, the present invention provides a dietary supplement for preventing or improving obesity comprising a taxlan extract.
본 발명에서 사용되는 용어 "개선"은, 치료되는 상태와 관련된 파라미터, 예를 들면 증상의 정도를 적어도 감소시키는 모든 행위를 의미한다. 이 때 상기 건강기능식품 조성물은 비만의 예방 또는 개선을 위하여 해당 질환의 발병 단계 이전 또는 발병 후, 치료를 위한 약제와 동시에 또는 별개로서 사용될 수 있다.As used herein, the term "improvement" refers to any action that at least reduces the parameters associated with the condition being treated, for example the extent of symptoms. At this time, the health functional food composition may be used simultaneously or separately with the agent for treatment before or after the onset of the disease for the prevention or improvement of obesity.
본 발명에서 "건강기능식품 조성물"은, 담체, 희석제, 부형제 및 첨가제 중 하나 이상을 포함하여 정제, 환제, 산제, 과립제, 분말제, 캡슐제 및 액제 제형으로 이루어진 군에서 선택된 하나로 제형된 것을 특징으로 한다. In the present invention, the "health food composition" is characterized in that it is formulated as one selected from the group consisting of tablets, pills, powders, granules, powders, capsules and liquid formulations, including one or more of carriers, diluents, excipients and additives. It is done.
본 발명의 추출물에 첨가 할 수 있는 식품으로는, 각종 식품류, 분말, 과립, 정제, 캡슐, 시럽제, 음료, 껌, 차, 비타민 복합제, 건강 기능성 식품류 등이 있다. 상기 본 발명에 더 포함될 수 있는 첨가제로는, 천연 탄수화물, 향미제, 영양제, 비타민, 광물(전해질), 풍미제(합성 풍미제, 천연 풍미제 등), 착색제, 충진제, 팩트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH조절제, 안정화제, 방부제, 산화 방지제, 글리세린, 알코올, 탄산화제, 및 과육으로 이루어진 군으로부터 선택된 1종 이상의 성분을 사용할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토오스, 수크로오스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알코올이다. 상기 향미제로서 천연 향미제(타우마틴, 스테비아추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. Foods that can be added to the extract of the present invention include various foods, powders, granules, tablets, capsules, syrups, beverages, gums, teas, vitamin complexes, and health functional foods. As additives which may be further included in the present invention, natural carbohydrates, flavoring agents, nutrients, vitamins, minerals (electrolytes), flavoring agents (synthetic flavoring agents, natural flavoring agents, etc.), colorants, fillers, pactic acid and salts thereof, Alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, antioxidants, glycerin, alcohols, carbonation agents, and one or more components selected from the group consisting of pulp can be used. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As the flavoring agent, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used.
상기 외에 본 발명에 따른 조성물은 여러 가지 영양제, 비타민, 광물 (전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제, 팩트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. In addition to the above, the composition according to the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and neutralizing agents, fact acids and salts thereof, alginic acid and salts thereof, organic acids, protection Sex colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages and the like.
그밖에 본 발명에 다른 조성물은 천연 과일 주스 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. In addition, other compositions of the present invention may contain pulp for the production of natural fruit juices and vegetable beverages. These components can be used independently or in combination.
상기 담체, 부형제, 희석제 및 첨가제의 구체적인 예로는 이에 한정하는 것은 아니나, 락토오스, 덱스트로즈, 수크로오스, 솔비톨, 만니톨, 에리스리톨, 전분, 아카시아 고무, 인산칼슘, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 미세결정성 셀룰로오스, 폴리비닐키롤리돈, 셀룰로오스, 폴리비닐피로리돈, 메틸셀룰로오스, 물, 설탕시럽, 메틸 하이드록시 벤조에이트, 프로필하이드록시 벤조에이트, 활석, 스테아르산 마그네슘, 및 미네랄 오일로 이루어진 그룹으로부터 선택된 1종 이상이 사용되는 것이 바람직하다.Specific examples of the carrier, excipient, diluent and additives include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, erythritol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium phosphate, calcium silicate, Group consisting of microcrystalline cellulose, polyvinylchirrolidone, cellulose, polyvinylpyrrolidone, methylcellulose, water, sugar syrup, methyl hydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate, and mineral oil It is preferred that at least one selected from be used.
이하, 본 발명의 바람직한 실시예 및 실험예를 첨부도면을 참조하여 상세히 설명하기로 한다. 다만, 이들 실시예 및 실험예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 이들 실시예 및 실험예에 의해 제한되는 것으로 해석되지는 않는다 할 것이다.Hereinafter, preferred embodiments and experimental examples of the present invention will be described in detail with reference to the accompanying drawings. However, these Examples and Experimental Examples are only for illustrating the present invention, and the scope of the present invention will not be construed as being limited by these Examples and Experimental Examples.
실시예1. 택란추출물의 제조Example 1 Preparation of Talan Extract
택란에 증류수를 첨가한 후 105℃에서 5시간 가압추출 하였으며, 추출횟수는 2회로 하였다. 추출 후 감압농축한 후 동결건조 시켜 택란추출물을 제조하였으며, 택란추출물의 수율은 15.44%로 산출되었다.After distilled water was added to the taxane, the extract was pressurized at 105 ° C. for 5 hours, and the extraction frequency was twice. After extraction, the extract was concentrated under reduced pressure, and then freeze-dried to prepare a lanthanum extract. The yield of the lanthanum extract was calculated to be 15.44%.
실험예1. 택란추출물에 의한 체중 변화 및 장기 중량 변화 분석Experimental Example 1. Analysis of Weight Change and Long Term Weight Change by Talan Extract
1-1. 체중 변화 분석1-1. Weight change analysis
식이성 비만 유도 마우스 모델에서 상기 실시예 1에서 제조한 택란추출물 섭취가 체중 증가에 미치는 영향을 알아보기 위하여, 도 1에 나타낸 모식도와 같이 실험을 디자인하여 진행하였다. 구체적으로, 4주령의 수컷 C57BL/6J 마우스(n=32)를 미국 잭슨사로부터 구입하여 일주일 동안 Lab chow로 적응사육시키고, 정상식이군(ND, n=10) 및 고지방식이군(HFD, n=22)으로 분류하여 4주동안 사육하며 일주일 간격으로 체중을 측정함으로써 비만이 잘 유도되었음을 관찰하였다. 이후 사육 4주차 시점에 고지방식이군(HFD, n=22)을 다시 고지방식이군 (HFD, n=12) 및 택란추출물 급여군(LT, 1.5%의 택란추출물+고지방식이, n=10)으로 각각 분류하여 13주 동안 사육하며 일주일 간격으로 체중을 측정하였다.In order to determine the effect of the intake of the taxlan extract prepared in Example 1 in the dietary obesity-induced mouse model, the experiment was designed and proceeded as shown in the schematic diagram shown in FIG. Specifically, four-week-old male C57BL / 6J mice (n = 32) were purchased from Jackson, USA, and adapted to Lab chow for one week, and were fed a normal diet group (ND, n = 10) and a high fat diet group (HFD, n =). It was observed that obesity was well induced by breeding for 4 weeks and weighing at weekly intervals. After 4 weeks of breeding, high-fat diet group (HFD, n = 22) and high-fat diet group (HFD, n = 12) and talan extract pay group (LT, 1.5% talancholine extract + high fat diet, n = 10) Each group was reared for 13 weeks and weighed at weekly intervals.
그 결과, 도 2에 나타낸 바와 같이, 고지방식이군(HFD)의 경우 정상식이군(ND)과 비교하여 체중이 급격하게 증가한 것에 반해 택란추출물 급여군(LT)의 경우 급여 일주일 후부터 고지방식이에 의해 증가된 체중을 유의적으로 감소시키는 것을 관찰하였다.As a result, as shown in Figure 2, in the case of the high-fat diet group (HFD) compared to the normal diet group (ND), the body weight increased dramatically, while in the case of the talan extract pay group (LT) a week after salary by the high-fat diet A significant decrease in the weight gain was observed.
1-2. 장기 중량 분석1-2. Long-term weight analysis
상기 실험예 1-1의 체중 변화 분석에 이어 식이성 비만 유도 마우스 모델에서 택란추출물 섭취가 장기 중량에 미치는 영향을 알아보고자 하였다. 이를 위해, 상기 실험예 1-1의 방법으로 17주간 사육한 각 군의 마우스들을 12시간 동안 절식시키고 이소플루란(isoflurane)(Baxter, USA)의 흡입을 통해 마취한 후 희생시키고 장기들을 적출하였다. 적출한 각 마우스의 간, 신장, 및 근육 조직을 인산완충액(PBS; phosphate buffered saline)으로 여러 번 헹구고 물기를 제거하여 중량을 측정한 후 체중 100 g 당 중량으로 나타내어 비교하였다.Following the weight change analysis of Experimental Example 1-1, the purpose of this study was to determine the effect of lanthanum extract intake on organ weight in a dietary obesity-induced mouse model. To this end, mice of each group bred for 17 weeks by the method of Experimental Example 1-1 were fasted for 12 hours, anesthetized through inhalation of isoflurane (isoflurane) (Baxter, USA), and sacrificed and organs were extracted. . Liver, kidney, and muscle tissues of each mouse were rinsed several times with phosphate buffered saline (PBS), drained, weighed, and expressed as weight per 100 g of body weight.
그 결과, 도 3에 나타낸 바와 같이, 간조직의 경우 정상식이군(ND)에 비하여 고지방식이군(HFD)의 중량이 유의하게 증가하였고, 택란추출물 급여군(LT)은 간 중량이 유의적으로 감소하였다. 또한, 단위 체중당 신장과 근육 중량은 고지방식이군이 정상식이군에 비해 유의하게 감소하였고, 택란추출물 급여군의 경우 신장과 근육 중량이 고지방식이군에 비하여 유의하게 증가하였다. 따라서, 상기 결과를 통해 택란추출물이 간 중량을 감소시키고, 신장과 근육의 중량은 증가시키는 것을 확인하였다. As a result, as shown in Figure 3, the liver tissue significantly increased the weight of the high-fat diet group (HFD) compared to the normal diet group (ND), the weight of the lanthanum extract supplement group (LT) significantly reduced liver weight It was. In addition, the height and muscle weight per unit weight was significantly decreased in the high-fat diet group compared to the normal diet group, and the height and muscle weight of the taxlan extract supplement group was significantly increased compared to the high-fat diet group. Therefore, it was confirmed through the above results that the lanthanum extract reduces the weight of liver and increases the weight of kidney and muscle.
실험예2. 택란추출물이 에너지 대사율에 미치는 영향 분석Experimental Example 2. Analysis of the Effect of Talan Extracts on Energy Metabolic Rate
택란추출물 섭취가 체중과 혈당강하 효과와 더불어 에너지 대사율(energy expenditure, EE)에도 영향을 미치는지 알아보고자 하였다. 이를 위해, 상기 실험예 1-1의 방법으로 마우스를 사육한 14주차에 동물대사율 측정장치(Oxylet; Panlab, Cornella, Spain)를 이용하여 마우스의 에너지 소비량을 측정하였다. 보다 구체적으로, 산소와 탄소로 측정기기를 캘리브레이션(calibration) 한 후 케이지 내 유량 속도를 3 L/min로 조절하였다. 이후 각 마우스를 분리된 대사 케이지에 넣고 24시간 동안의 에너지 소비량을 측정하였으며, 하기 수학식 1에 대입하고 계산하여 에너지 소비량을 도출하였다.The purpose of this study was to determine whether taxane extract intake affects energy expenditure (EE) as well as body weight and hypoglycemic effects. To this end, the energy consumption of the mouse was measured using the animal metabolic rate measuring device (Oxylet; Panlab, Cornella, Spain) at 14 weeks of breeding the mouse by the method of Experimental Example 1-1. More specifically, after calibrating the measuring device with oxygen and carbon, the flow rate in the cage was adjusted to 3 L / min. Thereafter, each mouse was placed in a separate metabolic cage, and the energy consumption for 24 hours was measured. Subsequently, the energy consumption was derived by substituting Equation 1 below.
[수학식 1][Equation 1]
EE(kcal/day/body weight0.75) = Vo2 ×1.44×[3.815+(1.232×Vo2/Vco2)]EE (kcal / day / body weight 0.75 ) = Vo 2 × 1.44 × [3.815+ (1.232 × Vo 2 / Vco 2 )]
그 결과, 도 4에 나타낸 바와 같이, 낮과 밤의 에너지 대사율을 각각 정량적으로 비교하였을 때, 고지방식이군(HFD)의 경우 정상식이군(ND)에 비하여 에너지 대사율이 유의적으로 낮게 나타난 반면, 택란추출물 급여군(LT)의 경우 낮 시간대에 고지방식이군에 비해 유의적으로 에너지 대사율이 높은 것을 확인하였다. 따라서, 상기 결과를 통해 택란추출물이 에너지 대사율을 증가시킴을 알 수 있었다. As a result, as shown in Figure 4, when the energy metabolic rate of day and night quantitatively compared, respectively, the high-fat diet group (HFD) showed a significantly lower energy metabolism rate compared to the normal diet group (ND), while The extract-feeding group (LT) was found to have a significantly higher energy metabolism rate during the day than the high-fat diet group. Therefore, the results showed that the lanthanum extract increases the energy metabolic rate.
실험예3. 택란추출물이 혈당 변화에 미치는 영향 분석Experimental Example 3. Analysis of the Effect of Talan Extracts on Blood Glucose Changes
상기 실험예 1-1 및 1-2의 결과를 통하여 상기 실시예 1에서 제조한 택란추출물의 섭취가 체중 및 간 중량을 감소시키는 효과가 있음을 확인하였으므로, 이에 더하여 혈당변화에도 영향을 미치는지 알아보고자 하였다. 이를 위해, 상기 실험예 1-1의 방법으로 4주 사육기간 동안 마우스를 12시간 동안 절식시키고 꼬리에서 채혈하여 공복혈당을 측정함으로써 고지방식이에 의한 혈당상승을 관찰한 후, 사육 4주차 시점에 고지방식이군을 다시 고지방식이군(HFD) 및 택란추출물 급여군(LT)으로 분류하여 12주 사육기간 동안 상기와 같은 방법으로 공복혈당을 측정하였다. It was confirmed through the results of Experimental Examples 1-1 and 1-2 that the intake of the taxane extract prepared in Example 1 has an effect of reducing body weight and liver weight. It was. To this end, the mice were fasted for 12 hours during the four-week breeding period by the method of Experimental Example 1-1, and blood glucose levels were measured by fasting blood glucose by measuring blood fastening by tailing. Fasting group was divided into high-fat diet group (HFD) and talan extract feed group (LT), and fasting blood glucose was measured in the same manner as above during the 12-week breeding period.
그 결과, 도 5에 나타낸 바와 같이, 고지방식이군(HFD)의 경우 정상식이군(ND)에 비해 유의적으로 증가된 혈당 수치를 유지한 반면, 택란추출물 급여군(LT)의 경우에는 12주 동안의 사육기간 전반에 걸쳐 고지방식이군에 비해 낮은 혈당수치를 유지하는 것을 확인하였다. 상기 결과를 통해, 택란추출물이 탁월한 혈당강하 효과가 있음을 알 수 있었다. As a result, as shown in FIG. 5, the high-fat diet group (HFD) maintained a significantly increased blood sugar level compared to the normal diet group (ND), while the lanthanum extract supplement group (LT) for 12 weeks. It was confirmed that the high-fat diet maintained lower blood sugar levels than the group fed throughout the breeding period. Through the above results, it was found that the taxlan extract has an excellent hypoglycemic effect.
실험예4. 택란추출물이 내당능에 미치는 영향 분석Experimental Example 4. Analysis of the Effect of Talan Extract on Glucose Tolerance
식후 혈당 농도 변화를 측정하고자 상기 실험예 1-1의 방법으로 마우스를 사육한 16주차에 마우스를 12시간 절식시킨 후 포도당 용액을 체중 kg당 0.5g씩 복강내로 투여한 뒤, 각각 0, 30, 60, 120 분 시간별로 꼬리정맥을 통해 채혈하여 혈당을 측정하였다. 혈당 측정 0분의 혈당 농도를 100으로 기준하여 각 시간대별 혈당 농도를 나타내었다.After the meal, the mice were fasted for 12 hours at week 16 when the mice were bred by the method of Experimental Example 1-1 to measure the change in blood glucose concentration after the administration of glucose solution intraperitoneally by 0.5 g / kg body weight, respectively, 0, 30, Blood glucose was measured by blood collection through the tail vein at 60 and 120 minutes. Blood glucose measurement The blood glucose concentration of each time period was represented based on the blood glucose concentration of 100 minutes.
그 결과, 도 6에 나타낸 바와 같이, 모든 실험군의 혈당은 당부하 30분 후에 최고치를 나타낸 후 60분후에 점차 감소되었으며, 택란추출물 급여군(LT)의 혈당은 모든 시간대에서 고지방식이군(HFD)에 비해 낮았으며 120분 후의 혈당이 고지방식이군(HFD)에 비해 유의적으로 감소하였다. 상기로부터, 택란추출물을 식이 보충할 경우 고지방식이로 인한 식후 혈당을 유의적으로 감소시켜 내당능을 개선 시킴을 확인하였다. As a result, as shown in Figure 6, the blood sugar of all the experimental group showed a peak after 30 minutes of glucose load gradually decreased after 60 minutes, the blood sugar of the lanthanide extract feeding group (LT) at all time periods (HFD) The blood sugar level after 120 minutes was significantly lower than that of the high-fat diet group (HFD). From the above, it was confirmed that when dietary supplementation of lanthanum extract significantly improved postprandial blood sugar due to high fat diet, thereby improving glucose tolerance.
이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적 기술은 단지 바람직한 실시 양태일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다.The specific parts of the present invention have been described in detail above, and it is apparent to those skilled in the art that such specific descriptions are merely preferred embodiments, and thus the scope of the present invention is not limited thereto. something to do. Thus, the substantial scope of the present invention will be defined by the appended claims and their equivalents.
본 발명에 따른 택란추출물을 유효성분으로 포함하는 조성물은 비만뿐만 아니라 체중 증가에 따라 유발될 수 있는 비만 관련 합병증의 예방, 치료, 또는 개선 용도로 유용하게 사용될 수 있을 것으로 기대된다.It is expected that the composition comprising the taxane extract according to the present invention as an active ingredient may be usefully used for the prevention, treatment, or improvement of obesity-related complications that can be caused by weight gain as well as obesity.
Claims (14)
- 택란추출물을 유효성분으로 포함하는, 비만 예방 또는 치료용 약학적 조성물.A pharmaceutical composition for preventing or treating obesity, comprising a taxlan extract as an active ingredient.
- 제1항에 있어서,The method of claim 1,상기 조성물은 체중의 증가를 억제시키는 것을 특징으로 하는, 비만 예방 또는 치료용 약학적 조성물.The composition is characterized in that to inhibit the increase in body weight, preventive or therapeutic pharmaceutical composition.
- 제1항에 있어서,The method of claim 1,상기 조성물은 에너지 대사율을 증가시키는 것을 특징으로 하는, 비만 예방 또는 치료용 약학적 조성물.The composition is characterized in that to increase the energy metabolic rate, obesity prevention or treatment pharmaceutical composition.
- 제1항에 있어서,The method of claim 1,상기 조성물은 혈당 증가를 억제시키는 것을 특징으로 하는, 비만 예방 또는 치료용 약학적 조성물.The composition is characterized in that to suppress the increase in blood glucose, obesity prevention or treatment pharmaceutical composition.
- 제1항에 있어서,The method of claim 1,상기 택란추출물은 택란에 추출용매를 첨가한 후 추출하는 단계; 및 추출된 추출물을 감압농축한 후 동결건조 하는 단계;Extracting the taxane extract after adding an extraction solvent to the taxane; And lyophilizing and then extracting the extracted extract under reduced pressure.를 통해 제조되는 것을 특징으로 하는, 비만 예방 또는 치료용 약학적 조성물.A pharmaceutical composition for preventing or treating obesity, characterized in that it is prepared through.
- 제5항에 있어서,The method of claim 5,상기 추출용매는 물, C1내지 C4의 저급알코올, n-헥산, 에틸아세테이트, 아세톤, 부틸아세테이트, 1,3-부틸렌 글리콜, 메틸렌클로라이드, 및 이들의 혼합용매로 구성된 군으로부터 선택된 1종인 것을 특징으로 하는, 비만 예방 또는 치료용 약학적 조성물.The extraction solvent is one selected from the group consisting of water, C 1 to C 4 lower alcohols, n-hexane, ethyl acetate, acetone, butyl acetate, 1,3-butylene glycol, methylene chloride, and mixed solvents thereof. Characterized in that for the prevention or treatment of obesity.
- 택란추출물을 유효성분으로 포함하는, 비만 예방 또는 개선용 건강기능식품 조성물.Health benefits food composition for the prevention or improvement of obesity comprising a lanthanum extract as an active ingredient.
- 제7항에 있어서,The method of claim 7, wherein상기 조성물은 체중의 증가를 억제시키는 것을 특징으로 하는, 비만 예방 또는 개선용 건강기능식품 조성물.The composition is characterized in that to suppress the increase in weight, obesity prevention or improvement health functional food composition.
- 제7항에 있어서,The method of claim 7, wherein상기 조성물은 에너지 대사율을 증가시키는 것을 특징으로 하는, 비만 예방 또는 개선용 건강기능식품 조성물.The composition is characterized in that to increase the energy metabolic rate, obesity prevention or improvement health functional food composition.
- 제7항에 있어서,The method of claim 7, wherein상기 조성물은 혈당 증가를 억제시키는 것을 특징으로 하는, 비만 예방 또는 개선용 건강기능식품 조성물.The composition is characterized in that to suppress the increase in blood sugar, obesity prevention or improvement health functional food composition.
- 제7항에 있어서,The method of claim 7, wherein상기 택란추출물은 택란에 추출용매를 첨가한 후 추출하는 단계; 및 추출된 추출물을 감압농축한 후 동결건조 하는 단계;Extracting the taxane extract after adding an extraction solvent to the taxane; And lyophilizing and then extracting the extracted extract under reduced pressure.를 통해 제조되는 것을 특징으로 하는, 비만 예방 또는 개선용 건강기능식품 조성물.A health functional food composition for preventing or improving obesity, characterized in that is prepared through.
- 제11항에 있어서,The method of claim 11,상기 추출용매는 물, C1내지 C4의 저급알코올, n-헥산, 에틸아세테이트, 아세톤, 부틸아세테이트, 1,3-부틸렌 글리콜, 메틸렌클로라이드, 및 이들의 혼합용매로 구성된 군으로부터 선택된 1종인 것을 특징으로 하는, 비만 예방 또는 개선용 건강기능식품 조성물.The extraction solvent is one selected from the group consisting of water, C 1 to C 4 lower alcohols, n-hexane, ethyl acetate, acetone, butyl acetate, 1,3-butylene glycol, methylene chloride, and mixed solvents thereof. A health functional food composition for preventing or improving obesity, characterized in that.
- 택란추출물을 유효성분으로 포함하는 조성물을 개체에 투여하는 단계를 포함하는, 비만 예방 또는 치료 방법.A method for preventing or treating obesity, comprising administering to a subject a composition comprising a taxlan extract as an active ingredient.
- 택란추출물을 유효성분으로 포함하는 조성물의 비만 예방 또는 치료 용도.Use for preventing or treating obesity in a composition comprising a lanthanum extract as an active ingredient.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2018-0011993 | 2018-01-31 | ||
| KR1020180011993A KR101910317B1 (en) | 2018-01-31 | 2018-01-31 | Composition for preventing, treating or improving obesity comprising extracts of Lycopus lucidus Turcz. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2019151767A1 true WO2019151767A1 (en) | 2019-08-08 |
Family
ID=64102175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2019/001281 WO2019151767A1 (en) | 2018-01-31 | 2019-01-30 | Composition containing lycopus lucidus turcz. extract as active ingredient for prevention, treatment, or alleviation of obesity |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR101910317B1 (en) |
| WO (1) | WO2019151767A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101910317B1 (en) * | 2018-01-31 | 2018-10-19 | 경북대학교 산학협력단 | Composition for preventing, treating or improving obesity comprising extracts of Lycopus lucidus Turcz. |
| KR102157662B1 (en) * | 2018-10-26 | 2020-09-18 | 대전대학교 산학협력단 | Compositions comprising extract of Crataegi fructus and Lycopus lucidus for prevention or treatment of lipid-related cardiovascular diseases or obesity |
| KR102517948B1 (en) | 2022-04-06 | 2023-04-06 | 한경수 | Pharmaceutical composition and health functional food for prevention or treatment of obesity containing complex medicinal herb extracts |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080050794A (en) * | 2006-12-04 | 2008-06-10 | 장용훈 | Composition comprising complex crude drug extract (mst) for preventing and treating obesity |
| KR20110087808A (en) * | 2010-01-27 | 2011-08-03 | 이경준 | Prevention of the obesity which contains the complex herb medicine extract (mdt), development of the therapeutic material and the composition development which treats constitutional by liver functional improvements and triglyceride decreases simultaneously |
| KR20170106013A (en) * | 2016-03-11 | 2017-09-20 | 유향자 | Preparation method of self-aggregation chitosan micelle comprising material fermented with herb |
| KR101910317B1 (en) * | 2018-01-31 | 2018-10-19 | 경북대학교 산학협력단 | Composition for preventing, treating or improving obesity comprising extracts of Lycopus lucidus Turcz. |
-
2018
- 2018-01-31 KR KR1020180011993A patent/KR101910317B1/en active IP Right Grant
-
2019
- 2019-01-30 WO PCT/KR2019/001281 patent/WO2019151767A1/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080050794A (en) * | 2006-12-04 | 2008-06-10 | 장용훈 | Composition comprising complex crude drug extract (mst) for preventing and treating obesity |
| KR20110087808A (en) * | 2010-01-27 | 2011-08-03 | 이경준 | Prevention of the obesity which contains the complex herb medicine extract (mdt), development of the therapeutic material and the composition development which treats constitutional by liver functional improvements and triglyceride decreases simultaneously |
| KR20170106013A (en) * | 2016-03-11 | 2017-09-20 | 유향자 | Preparation method of self-aggregation chitosan micelle comprising material fermented with herb |
| KR101910317B1 (en) * | 2018-01-31 | 2018-10-19 | 경북대학교 산학협력단 | Composition for preventing, treating or improving obesity comprising extracts of Lycopus lucidus Turcz. |
Non-Patent Citations (2)
| Title |
|---|
| BUCHHOLZ, T. ET AL.: "Pancreatic lipase and a-amylase inhibitory activities of plants used in Traditional Chinese Medicine (TCM)", DIE PHARMAZIE-AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 71, no. 7, 7 July 2016 (2016-07-07), pages 420 - 424 * |
| YANG, MI-OK: "Antioxidant Properties of Hot Water Extract of Lycopus lucidus Trucz Tubers", KOREAN J COMMUNITY LIVING SCI., vol. 28, no. 1, 28 February 2013 (2013-02-28), pages 103 - 113, XP055627999 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101910317B1 (en) | 2018-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019151767A1 (en) | Composition containing lycopus lucidus turcz. extract as active ingredient for prevention, treatment, or alleviation of obesity | |
| US7968128B2 (en) | Plant extract compositions for affecting sleep | |
| WO2021215598A1 (en) | Composition for prevention or treatment of epilepsy and preparation method therefor | |
| KR102225574B1 (en) | Composition for preventing, treating or improving obesity or obesity-related disease comprising extracts of Angelica tenuissima | |
| KR101685876B1 (en) | Pharmaceutical composition comprising the extract of Platycodon grandiflorum for preventing or treating of obesity | |
| RU2540511C2 (en) | Pharmaceutical composition and food functional therapeutic composition for preventing, treating or relieving gastrointestinal dysmotilities | |
| EP3263114A1 (en) | Use of albiflorin or pharmaceutically acceptable salt for prevention and/or treatment of irritable bowel syndrome | |
| CN108367039B (en) | Composition for treating or preventing liver disease comprising Citrullus spinosa extract as active ingredient | |
| WO2016167444A1 (en) | Pharmaceutical composition for preventing or treating obesity or lipid-related metabolic diseases, containing atractylodis macrocephalae rhizoma extract | |
| WO2018030650A1 (en) | Anti-obesity composition containing chrysanthemum leaf extract as active ingredient | |
| WO2020085799A1 (en) | Pharmaceutical composition for prevention or treatment of liver disease comprising platycodon grandiflorum saponin-containing standardized platycodon grandiflorum extract or membrane-separated platycodon grandiflorum saponin extract, and health functional food for liver function amelioration | |
| WO2014133286A1 (en) | Composition containing extracts of artemisia iwayomogi and curcuma longa as active ingredients for preventing, inhibiting, or treating obesity-related diseases | |
| WO2018008973A1 (en) | Composition comprising forsythiae fructus extract as effective ingredient for preventing, ameliorating or treating peripheral neuropathy | |
| WO2018084336A1 (en) | Pharmaceutical composition for prevention or treatment of liver cancer and health functional food | |
| WO2017069476A1 (en) | Composition for prevention or treatment of liver diseases, containing fraction of moutan radicis cortex extract | |
| WO2021070999A1 (en) | Composition for preventing, ameliorating, or treating metabolic syndromes including obesity, diabetes, hyperlipidemia, and fatty liver | |
| KR20130088783A (en) | Compositions for preventing or treating multiple sclerosis | |
| WO2020122385A1 (en) | Composition comprising elecampane extract for alleviating premenstrual syndrome symptom | |
| KR20210000294A (en) | Pharmaceutical composition comprising the extract of Phlomis umbrosa Turczaninow as an effective ingredient for preventing or treating of obesity | |
| KR102232330B1 (en) | Composition for preventing, treating or improving obesity or obesity-related disease comprising extracts of Lindera obtusiloba Blume leaf | |
| WO2019088381A1 (en) | Composition for preventing, ameliorating or treating obesity and metabolic diseases, comprising complex extract from peach blossom and lotus leaf | |
| WO2019004626A1 (en) | Composition for preventing or treating menopausal syndrome, containing medicinal herb extract as active ingredient | |
| WO2010062046A1 (en) | Composition for prevention and treatment of irritable bowel syndrome | |
| WO2017082547A1 (en) | Composition for alleviating, preventing or treating premenstrual syndrome, containing, as active ingredient, pinitol, d-chiro-inositol or analog compound thereof | |
| WO2023085703A1 (en) | Composition for curing hangover or improving liver function, comprising pine heartwood extract as active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19748209 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 19748209 Country of ref document: EP Kind code of ref document: A1 |